Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 2,293 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cardiac Ischemia Clear all

Conditions: Acute Coronary Syndrome, Angina, Unstable
Interventions: Ticagrelor, Eptifibatide, Clopidogrel; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Heart Failure, Systolic
Interventions: CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs), Diagnostic Catheterization; Combination Product · Diagnostic Test
Lead sponsor: BioCardia, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Chronic Total Occlusion of Coronary Artery, Angina Pectoris, Quality of Life, PROM
Interventions: Chronic total occlusion(CTO) percutaneous coronary intervention (PCI); Procedure
Lead sponsor: Haukeland University Hospital; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Myocardial Reperfusion Injury
Interventions: BQ-123, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Ischemic Heart Disease
Interventions: umbilical cord-derived mesenchymal stromal cells (UC-MSCs); Biological
Lead sponsor: Roberto Bolli; Other
Eligibility: 21 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Miami, Florida • Louisville, Kentucky • Houston, Texas

Conditions: Coronary Artery Disease
Interventions: Ticagrelor 90 mg, Prasugrel 10 mg; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Coronary Artery Disease
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 95 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Coronary Artery Disease, Atherosclerosis, Stent Placement
Interventions: Dual Antiplatelet (DAPT) Therapy, The Synergy® stent; Drug · Device
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 75 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Scottsdale, Arizona • Boston, Massachusetts • New York, New York

Conditions: Type 2 Diabetes, Microvascular Dysfunction
Interventions: Intensive risk factor management; Other
Lead sponsor: University of Virginia; Other
Eligibility: 21 Years to 85 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Coronary Artery Disease, Sternal Pain
Interventions: Bupivacaine Group, Placebo; Drug · Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Coronary Artery Disease
Interventions: Financial incentives; Behavioral
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Acute Coronary Syndrome, Angioplasty, Transluminal, Percutaneous Coronary, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Blood Platelets
Interventions: rosuvastatin, placebo; Drug
Lead sponsor: Susan Smyth; Other
Eligibility: 18 Years to 80 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting
Interventions: Single arterial graft, Multiple arterial grafting; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 42
States / cities: Los Angeles, California • Pomona, California • San Francisco, California + 36 more

Conditions: Coronary Artery Disease
Interventions: low-dose ticagrelor, Clopidogrel; Drug
Lead sponsor: First Affiliated Hospital of Harbin Medical University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: San Diego, California

Conditions: Heart Failure
Interventions: Not listed
Lead sponsor: Impulse Dynamics; Industry
Eligibility: 18 Years and older
Enrollment: 5,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2036
U.S. locations: 30
States / cities: Mesa, Arizona • Phoenix, Arizona • Surprise, Arizona + 23 more

Conditions: Coronary Artery Disease
Interventions: Ticagrelor 180mg, Ticagrelor 270mg, Ticagrelor 360mg; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Coronary Artery Disease
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Coronary Artery Disease, Myocardial Infarction
Interventions: IVL with Shockwave C2+ 2Hz Coronary IVL Catheter; Device
Lead sponsor: Shockwave Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 18
States / cities: Huntsville, Alabama • La Jolla, California • Washington D.C., District of Columbia + 15 more

Conditions: Coronary Artery Disease Risk Factors Multiple, Coronary Artery Disease Progression, Prevention & Control, Premature Atherosclerosis
Interventions: Rosuvastatin 20 Mg Oral Tablet, Colchicine 0.5 MG Oral Tablet Once Daily, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 30 Years to 60 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 23
States / cities: Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 18 more

Conditions: Myocardial Infarction, Percutaneous Transluminal Coronary Angioplasty, Coronary Artery Bypass, Stable Angina, Heart Failure, Valve Disease, Heart, Cardiac Rehabilitation, Stent
Interventions: ROMTech Portable Connect; Device
Lead sponsor: ROM Technologies, INC; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Brookfield, Connecticut

Conditions: Chest Pain, Acute Coronary Syndrome, Pulmonary Embolism, Aortic Dissection
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 30 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Acute Coronary Syndrome
Interventions: ADP receptor inhibitors; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 12,227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 185
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 182 more

Conditions: Cardiogenic Shock
Interventions: Vasopressor, Inotrope, Acute Mechanical Circulatory Support Devices; Drug · Device
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 16
States / cities: Weston, Florida • Chicago, Illinois • Portland, Maine + 10 more

Conditions: Myocardial Ischemia
Interventions: Sonazoid; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 19 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel

Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells

Invest-CTO PCI Trial

Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI

Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy

Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors

Magnetic Resonance Imaging (MRI) Viability: Comparison of Myocardial Viability by Positron Emission Tomography and MRI

SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy

Less Invasive Detection and Treatment of Very Early Coronary Artery Disease in Patients With Diabetes Mellitus

Pecto-Intercostal Fascial Block for Postoperative Analgesia After Cardiac Surgery

Increasing Cardiac Rehabilitation Participation Among Medicaid Enrollees

Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions

Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

Safety and Efficacy of Low-dose Ticagrelor in Chinese Patients With Stable Coronary Artery Disease

CCM OPEN HF Registry

High Ticagrelor Loading Dose in STEMI

Identification of Carotid Vasa Vasorum and Correlation With Acute Coronary Events

Shockwave C2+ 2Hz Coronary IVL Catheter in Calcified Coronary Arteries (Disrupt CAD DUO)

PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis

Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence

Diagnostic Accuracy of Multislice CT Angiography for Acute Chest Pain

Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome

Cardiogenic Shock Working Group Registry

Ischemic Memory Imaging With Myocardial Contrast Echocardiography